Sumary Saos-2 cells, derived from a primary human osteosarcoma, caused dose-dependent platelet aggregation in heparinised human platelet-rich plasma. Saos-2 tumour cell-induced platelet aggregation (TCIPA) was completely inhibited by hirudin but unaffected by apyrase. The cell suspension shortened the plasma recalcification times of normal, factor VIII-deficient and factor IX-deficient human plasmas in a dosedependent manner. However, the cell suspension did not affect the recalcification time of factor VII-deficient plasma. Moreover, a monoclonal antibody (MAb) against human tissue factor completely abolished TCIPA. Flow cytometric analysis using anti-integrin MAbs as the primary binding ligands demonstrated that the integrin receptors cvP3, 1 and ae8B were present on the surface of Saos-2 cells, which might mediate tumour cell adhesion to extracellular matrix. Rhodostomin, an Arg-Gly-Asp (RGD)-containing snake venom peptide which antagonises the binding of fibnrnogen to platelet membrane glycoprotein i1b/i11a, prevented Saos-2 TCIPA as well as tumour cell adhesion to vitronectin, fibronectin and collagen type I. Likewise, the synthetic peptide Gly-Arg-Gly-Asp-Ser (GRGDS) showed a similar effect. On a molar basis, rhodostomin was about 18 000 and 1000 times. respectively, more potent than GRGDS in inhibiting TCIPA and tumour cell adhesion.
The formation of a metastatic lesion is the result of a complex series of events called the 'metastatic cascade'. Following intravasation, circulating tumour cells interact with a variety of host cells such as effectors of the cellular immune responses, endothelial cells and platelets. The interaction of tumour cells and host platelets may promote the metastatic process (Honn et al., 1992) . Indeed, there is evidence that the incidence of lymph node metastasis caused by ten cell lines, from rat renal carcinoma, in vivo correlates well with their ability to induce platelet aggregation in vitro (Pearlstein et al., 1980) .
Platelets may enhance tumour cell adhesion to endothelial cells and subendothelial surfaces during the haematogenous metastasis process. The cell-cell or cell-extracellular matrix (ECM) interactions of both normal and tumour cells have been proven to be mediated by a variety of plasma membrane receptors including the integrin family (Hynes et al., 1987) . Integrins are transmembrane proteins which link the ECM with the cell cytoskeleton. Such linkage enables cellular attachment to substrata and forms focal adhesion plaques in distinct plasma membrane regions which establish contact with the matrix (Grunicke, 1990) . The interaction of integrins with adhesion proteins has been shown to be partially mediated by binding of integrin to Arg-Gly-Asp (RGD), the short hydrophilic amino acid sequence within adhesion proteins (Pierschbacher and Rouslahti, 1984; Rouslahti and Pierschbacher, 1987) .
Purified components from snake venoms have been widely studied and found to affect platelet function, including trigramin-like anti-platelet peptides (Huang et al., 1987a (Huang et al., , 1991a Shebuski et al., 1989; Rucinski et al., 1990) . Trigramin, an RGD-containing peptide purified from venom of the Trimeresurus gramineus snake, is a specific antagonist of platelet membrane glycoprotein Ib/Illa (Huang et al., 1987a (Huang et al., , 1989 . Rhodostomin, another RGD-containing peptide purified from the venom of the Malayan pit viper Agkistrodon rhodostoma, also inhibits platelet aggregation by antagonism of the Gp Ilb/Illa-fibrinogen interaction (Huang et al., 1987b . These peptides all contain the RGD sequence, are rich in cysteine and bind with high affinity to the surface of platelets.
The in vitro metastatic characterisation of osteosarcoma is not yet well understood. In the present study, we examined in vitro the TCIPA caused by Saos-2 human osteosarcoma cells. We probed Saos-2 TCIPA with a variety of inhibitors and monoclonal antibodies in order to characterise fully the mechanism of this phenomenon. Rhodostomin was found to inhibit potently both TCIPA and tumour cell adhesion to ECM (i.e. fibronectin, vitronectin, collagen type I), which is closely related to the binding characterisation of RGDdependent rhodostomin to the integrins expressed on the Saos-2 cell surface.
Materals and metbods
Materials Saos-2 human osteosarcoma cells were obtained from ATCC (American Type Culture Collection) Laboratory. Crude venom of Agkistrodon rhodostoma (or Calloselasma rhodostoma) was purchased from Latoxan (Rosans, France) and stored at -20°C. Rhodostomin was purified from venom of A. rhodostoma as previously described (Huang et al., 1989 . GRGDS was purchased from Peninsula Laboratories, CA, USA. Gly-Arg-Gly-Glu-Ser (GRGES) was synthesised by the Biochemical Institute, College of Medicine, National Taiwan University. Apyrase (grade III), heparin, hirudin (grade IV from leeches), fibronectin (from bovine plasma), vitronectin (from human plasma), laminin (from basement membrane of mouse sarcoma), collagen type I (from calf skin) and type IV were obtained from Sigma (St Louis, MO, USA 
Aggregation studies
Human blood was anticoagulated with heparin (final concentration I U ml-'). Platelet-rich plasma (PRP) was prepared by centrifugation at 120 g for O min at room temperature. Platelet-poor plasma (PPP) was prepared from the remaining blood by additional centrifigation at 500 g for 10 min PRP was adjusted with PPP to contain about 3 x 10' platelets/ml.
Platelet aggregation was measured turbidimetrically with a Lumi-aggregometer (Chrono-log). PRP (400 gi) was prewarmed at 37C for 2 min in a si ne-treated g cuvette.
Each inhibitor, snake venom, monoclonal antibody or peptide was added at various tmes before addition of 20 gl of .cell suspension (3 x I 04 cells ml-', final concentration). The reaction was allowed to proceed for at least 10 min and the degree of aggregation expressed as changes in light transmis sion.
Meaurement ofprocoagulant activity
Procoagulant activity of the cell suspension was measured by plasma recakification time (Sheu et al., 1992) . PPP was prepared from whole blood, collected from healthy human volunteers and mixed with 3.8% (w/v) sodium citrate (9: 1, v/v). In brief, 100 id of either fresh normal citrated PPP or human factor-deficient plamas (deficient in factor VII, VIII or IX) was incubated with 100 gi of cell suspension containing various concentrations of tumour cells for 2 min at 3TC.
Thereafter, 100 PI of prewarmed 25 mM calcium chloride was added, and the plasma clotting time determined by a fibrometry (Coag-a-mate, Organon Teknika, NC, USA). Tisu thromboplastin was used as a positive control for activating the extrinsic coagulation pathway.
Fow cytometric analysis
Flow cytometric studies were performed to quantify surface expression of integrins (Grossi et al., 1989) . Cells were detached (using 0.5 mM EDTA), washed free of serum proteis with Hanks' balanced salt solution (HBSS, pH 7.25) containing 2 mM Ca2+ and 2 mM Mg2+, then finally suspended at a concentration of 106 cells per sample. Cells were fixed with paraformaldehyde (0.07%, 10 min) prior to labelling for surface integrins. The fixed cells were blocked with normal goat serum (1:2) for 25 min, and labelled with MAbs (25 pg ml-') for I h. After washing, cells were finally relabelled with goat anti-mouse IgG-FITC. FITC signals were detected and digitised in logarithmic configuration and the data collected on a EPICS computer system. Data were collected at 256-channel resolution and 10 000 cells were counted per experimental group. Fluorescence intensity was directly proportional to the fluorescein label present on the tumour cell surface. The control fluorescence intensity was obtained with cell suspension in which primary antibodies were omitted. All experiments were repeated at least four times.
Adhesion studies 2',7'-Bis-(2-carboxyethyl)-5(and-6)-carboxyfluorescein acetoxymethyl (BCECF-AM) has been used in fluorescence-based viability assesent in adherent cell cultures (Vaporciyan et al., 1993 The Saos-2 cell suspension was a potent inducer of irreversible platelet aggregation in heparinised human PRP ( Figure  1 ). This TCIPA was dose dependent and preceded by a lag phase. Cells at concentrations of more than 5 x I03 cells ml-' caused aggregation. The tracings of aggregation induced by at least 5 x 10' cells ml-' were interrupted by delayed fibrin clot formation (Figure 1 ), which was also grossly evident. The lag phase preceding aggregation became progressively shorter with increasing tumour cell concentrations.
Cell suspension at 3 x 1O' cells ml-' was used for the following platelet aggregation studies. Pretreatment with the ADP scavenger apyrase (0.5 U ml-', final concentration) in PRP did not inhibit TCIPA (Figure 2 ), indicating that ADP is essentially not involved. However, the lag phase preceding TCIPA was prolonged. Hirudin (5 U ml-'), a specific thrombin inhibitor, completely inhibited the aggregation response (Figure 2 ), suggesting that formation of thrombin is required for Saos-2 TCIPA.
Effect of Saos-2 cells on the plasma recalcfication tine As shown in Table I , Saos-2 cell suspension shortened the one-stage recacification time of normal human citrated PPP in a concentration-dependent manner. The clotting times of factor VIII-and factor IX-deficient plasmas were similarly shortened. However, cell suspension did not shorten the recacification time of factor VII-deficient plasma. A similar pattern of results was obtained with control thromboplastin. These data indicated that the procagulant activity of Saos-2 cells is via activation of factor VII in the extrinsic coagulation pathway, leading to the activation of the common pathway.
Effect of rhodostomin and monoclonal antibodies on Saos-2
TCIPA
The binding of fibrinogen to its specific receptor is mainly through the peptide sequence RGD in fibrinogen (Plow et al., 1986) . Pretreatment of platelets with rhodostomin, an RGDcontaining snake venom peptide (0.5 pg ml-'), complely inhibited Saos-2 TCIPA. This inhibition was also observed with synthetic peptide GRGDS (500 pg ml-'), while GRGES (I mg ml-') had no significant effect. Either snake venom a peptide or GRGDS inhibited TCIPA in a dose-dependent manner (Figure 3) . On a molar basis, rhodostomin (IC,. 0.03 pM) is a 18 000-fold more potent than GRGDS (ICO. 0.56mM). Pretreatment with MAb 7E, (25 fig ml-' ) against the platelet membrane GP Ilb Illa complex completely inhibited TCIPA (Figure 2) rhodostomin in a do'-e-dependent manner. At (._ pNi. rhodostomin inhibited ce11 adhesion to collaen txpe I. xitronectin and fibronectin b! approximately 90o5. However. even at higher concentration i. /. pm rhodostomin on1v -'lightlx inhibited cell adhesion to laminin le'-than 200 5. and it had no inhibitorx effect on cell adhesion to collagen t!pe IV. Synthetic peptide GRGDS s-howed a s-imilar inhibitorx pattern iFizure 6i. On a molar basis. rhodostomin iW 1000-fCold more potent than GRGDS in inhibiting Sao--' cell adhesion to RGD-dependent ECNI. Our results indicate that Saos-2 TCIPA is thrombin dependent and that ADP is not fundamentally involved. During the lag period of platelet aggregation, the accumulation of thrombin sufficient to trigger aggregation was required. This is consistent with the observation reported elsewhere that thrombin inhibitors prolong the lag period in a dose-dependent manner, but do not influence the maximum response of aggregation once platelets begin to aggregate (Pearistein et al., 1981) . Although Saos-2 TCIPA was essentially thrombin dependent, apyrase was found to prolong the lag phase preceding TCIPA. This is also observed with other human colon adenocarcinoma lines, colo 205 and colo 397 (Scarlett et al., 1987) . The reason may reside in the rate or amount of thrombin generation. Low concentrations of thrombin are thought to mediate platelet aggregation in part by triggering platelet release of ADP, whereas higher concentrations of thrombin will produce aggregation independent of ADP release (Kinlough-Rathbone et al., 1977) .
Integrin-mediated cell adhesion has been demonstrated for several RGD-containing proteins found in the mineral compartment of bone (Weiss and Reddi, 1980; Oldberg et al., 1986; Gehron et al., 1989) . RGD also appears to be the active epitope in most disintegrins (Gould et al., 1990) . In this study, we detected various integrins (i.e. vP3, 5l and aJl) expressed on Saos-2 cels by flow cytometric analysis.
Saos-2 cells do not express integrin ac3, unlike human colon adenocarcinoma cells (SW-480) and prostate adenocarcinoma cells (PC-3) (data not shown). We showed that rhodostomin inhibits adhesion of Saos-2 cells to several ECM (i.e., fibronectin, vitronectin and collagen type I), probably by interfering with several epitopes of the RGDdependent integrin receptors. The synthetic peptide GRGDS has a similar inhibitory effect on adhesion to these ECM, further confirming that the tripeptide sequence Arg-Gly-Asp is important for receptor recognition. In the study of TCIPA, both rhodostomin and GRGDS and the MAb raised against GP Hb/HIIa had an inhibitory effect through blockade of fibrinogen binding to its platelet surface receptor.
A growing body of evidence strongly suggests that platelets are indispensable in enabling metastasis. In this study, we showed that Saos-2 human osteosarcoma cells act as a potent inducer of platelet aggregation and that thrombin-dependent 
